Overview

Prophylactic Antimalarial Activity of DB289 in Volunteers

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the prophylactic activity of orally administered DB289 against Plasmodium falciparum in non-immune healthy volunteers who are challenged by the bite of five P. falciparum-infected Anopheles stephensi mosquitoes
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Immtech Pharmaceuticals, Inc
Treatments:
Antimalarials
Pafuramidine